The electric kool-aid clinical trial

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

The developments and research in the field of psychedelic drugs for curing mental illness, are discussed. John Halpern, associate director of substance abuse at Harvard university, has received approval from the US Food and Drug Administration (FDA) to give late-stage cancer patients the psychedelic drug MDMA. Since 2001, psychiatrist Francisco Moreno of the University of Arizona in Tucson has been testing psilocybin as a treatment for obsessive-compulsive disorder. In Charlston, South Carolina, physician Michael Mithoefer is carrying out a MAPS-sponsored clinical trial of MDMA as a treatment for post-traumatic stress disorder, in which he has given MDMA-assisted psychotherapy to six treatment-resistant patients, all traumatized by violent crimes.

Original languageEnglish
Pages (from-to)36-39
Number of pages4
JournalNew Scientist
Volume185
Issue number2488
StatePublished - 26 Feb 2005

Fingerprint

Dive into the research topics of 'The electric kool-aid clinical trial'. Together they form a unique fingerprint.

Cite this